Framingham Biopharma Preps for Preeclampsia Market in Marlborough Expansion
Worcester Business Journal - July 16, 2015
Framingham biopharmaceutical firm LFB USA has pinned plans to build a new 65,000-square-foot manufacturing and laboratory facility in Marlborough in part on the expectation that its drug, ATryn, will soon receive FDA approval for the treatment of preeclampsia.